Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

• Published in: The New England journal of medicine Vol. 391; no. 5; pp. 393 - 407
• Main Authors: Hungria, Vania, Robak, Pawel, Hus, Marek, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, Ribas de Almeida, Ana Carolina, Hajek, Roman, Kim, Kihyun, Grosicki, Sebastian, Sia, Hanlon, Bryant, Adam, Pitombeira de Lacerda, Marcelo, Aparecida Martinez, Gracia, Sureda Balarí, Anna Maria, Sandhu, Irwindeep, Cerchione, Claudio, Ganly, Peter, Dimopoulos, Meletios, Fu, Chengcheng, Garg, Mamta, Abdallah, Al-Ola, Oriol, Albert, Gatt, Moshe E., Cavo, Michele, Rifkin, Robert, Fujisaki, Tomoaki, Mielnik, Michał, Pirooz, Nick, McKeown, Astrid, McNamara, Simon, Zhou, Xiangdong, Nichols, Maureen, Lewis, Eric, Rogers, Rachel, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Mateos, María-Victoria
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 01.08.2024
• Subjects: Acuity; Adult; Adverse events; Aged; Aged, 80 and over; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Bortezomib - therapeutic use; Confidence intervals; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Dexamethasone - therapeutic use; Female; Hematology; Humans; Hypothesis testing; Inhibitor drugs; Kaplan-Meier Estimate; Leukemia; Lymphoma; Male; Middle Aged; Minimal residual disease; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Neoplasm, Residual; Oncology; Patients; Progression-Free Survival; Quality of life; Statistical analysis; Survival; Survival Analysis; Targeted cancer therapy; Treatments in Oncology; Visual acuity
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2405090

Among patients with relapsed myeloma, median progression-free survival was approximately 3 years with a regimen including belantamab mafodotin, as compared with 13 months with a regimen including an anti-CD38 antibody.